5 news items
NKGen Biotech Presents Updated Phase 1 Data on SNK02 Allogeneic NK Cell Therapy for Solid Tumors at the 6th Annual Allogeneic Cell Therapies Summit 2024
NKGN
12 Jun 24
inhibitors, monoclonal antibodies or bispecific therapies where a robust immune response is essential. We therefore set out to develop a commercial
Spotlighting Unexplored Stocks in Focus: NKGN, INBS, BTBT, PRSO, MGOL
BTBT
INBS
MGOL
24 May 24
profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content."TSR" is not operated by a licensed broker, a dealer
NKGen Biotech Publishes Phase 1 Interim Analysis Results of SNK02 Allogeneic NK Cell Therapy in Advanced Solid Tumors at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
NKGN
23 May 24
. In this Phase 1 trial, the best objective response of stable disease was demonstrated in 100% of patients that completed 8 treatment cycles of SNK02
Why NKGen Biotech Stock Is Moving Higher Monday
NKGN
20 May 24
safe and able to cross the blood brain barrier to reduce amyloid, tau, and alpha-synuclein proteins as well as neuroinflammation in a dose responsive
NKGen Biotech's SNK01 NK Cell Therapy Cleared to Start Phase 2 Clinical Trial in Alzheimer's Disease
NKGN
20 May 24
barrier to reduce amyloid, tau, and alpha-synuclein proteins as well as neuroinflammation in a dose responsive manner. Despite only receiving four doses, 90
- Prev
- 1
- Next